Literature DB >> 28289093

A hot spot on interferon α/β receptor subunit 1 (IFNAR1) underpins its interaction with interferon-β and dictates signaling.

Nicole A de Weerd1,2, Antony Y Matthews3,2, Phillip R Pattie3, Nollaig M Bourke3,2, San S Lim3,2, Julian P Vivian4,5, Jamie Rossjohn4,5,6, Paul J Hertzog7,2.   

Abstract

The interaction of IFN-β with its receptor IFNAR1 (interferon α/β receptor subunit 1) is vital for host-protective anti-viral and anti-proliferative responses, but signaling via this interaction can be detrimental if dysregulated. Whereas it is established that IFNAR1 is an essential component of the IFNAR signaling complex, the key residues underpinning the IFN-β-IFNAR1 interaction are unknown. Guided by the crystal structure of the IFN-β-IFNAR1 complex, we used truncation variants and site-directed mutagenesis to investigate domains and residues enabling complexation of IFN-β to IFNAR1. We have identified an interface on IFNAR1-subdomain-3 that is differentially utilized by IFN-β and IFN-α for signal transduction. We used surface plasmon resonance and cell-based assays to investigate this important IFN-β binding interface that is centered on IFNAR1 residues Tyr240 and Tyr274 binding the C and N termini of the B and C helices of IFN-β, respectively. Using IFNAR1 and IFN-β variants, we show that this interface contributes significantly to the affinity of IFN-β for IFNAR1, its ability to activate STAT1, the expression of interferon stimulated genes, and ultimately to the anti-viral and anti-proliferative properties of IFN-β. These results identify a key interface created by IFNAR1 residues Tyr240 and Tyr274 interacting with IFN-β residues Phe63, Leu64, Glu77, Thr78, Val81, and Arg82 that underlie IFN-β-IFNAR1-mediated signaling and biological processes.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  interferon; mutagenesis; receptor; signal transduction; structure-function

Mesh:

Substances:

Year:  2017        PMID: 28289093      PMCID: PMC5418053          DOI: 10.1074/jbc.M116.773788

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  The interferons: 50 years after their discovery, there is much more to learn.

Authors:  Sidney Pestka
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.

Authors:  Peter Lamken; Martynas Gavutis; Imke Peters; José Van der Heyden; Gilles Uzé; Jacob Piehler
Journal:  J Mol Biol       Date:  2005-07-15       Impact factor: 5.469

Review 6.  IFN-β and multiple sclerosis: from etiology to therapy and back.

Authors:  V Annibali; R Mechelli; S Romano; M C Buscarinu; A Fornasiero; R Umeton; V A G Ricigliano; F Orzi; E M Coccia; M Salvetti; G Ristori
Journal:  Cytokine Growth Factor Rev       Date:  2014-10-31       Impact factor: 7.638

7.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

8.  Upregulation of a small subset of genes drives type I interferon-induced antiviral memory.

Authors:  Diego A Jaitin; Gideon Schreiber
Journal:  J Interferon Cytokine Res       Date:  2007-08       Impact factor: 2.607

9.  The pathological effects of CCR2+ inflammatory monocytes are amplified by an IFNAR1-triggered chemokine feedback loop in highly pathogenic influenza infection.

Authors:  Sue-Jane Lin; Ming Lo; Rei-Lin Kuo; Shin-Ru Shih; David M Ojcius; Jean Lu; Chien-Kuo Lee; Hui-Chen Chen; Meei Yun Lin; Chuen-Miin Leu; Chia-Ni Lin; Ching-Hwa Tsai
Journal:  J Biomed Sci       Date:  2014-11-18       Impact factor: 8.410

10.  Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice.

Authors:  Jennifer A Stokes; Jonathan Cheung; Kelly Eddinger; Maripat Corr; Tony L Yaksh
Journal:  J Neuroinflammation       Date:  2013-12-09       Impact factor: 8.322

View more
  13 in total

1.  Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.

Authors:  Sebastian A Stifter; Antony Y Matthews; Niamh E Mangan; Ka Yee Fung; Alexander Drew; Michelle D Tate; Tatiana P Soares da Costa; Daniel Hampsey; Jemma Mayall; Phil M Hansbro; Albert Garcia Minambres; Sahar G Eid; Johnson Mak; Judy Scoble; George Lovrecz; Nicole A deWeerd; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

Review 2.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

3.  Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.

Authors:  Marissa C Locke; Lindsey E Fox; Bria F Dunlap; Alissa R Young; Kristen Monte; Deborah J Lenschow
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

4.  Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency.

Authors:  Paul Bastard; Jeremy Manry; Jie Chen; Jérémie Rosain; Yoann Seeleuthner; Omar AbuZaitun; Lazaro Lorenzo; Taushif Khan; Mary Hasek; Nicholas Hernandez; Benedetta Bigio; Peng Zhang; Romain Lévy; Shai Shrot; Eduardo J Garcia Reino; Yoon-Seung Lee; Soraya Boucherit; Mélodie Aubart; Rik Gijsbers; Vivien Béziat; Zhi Li; Sandra Pellegrini; Flore Rozenberg; Nico Marr; Isabelle Meyts; Bertrand Boisson; Aurélie Cobat; Jacinta Bustamante; Qian Zhang; Emmanuelle Jouangy; Laurent Abel; Raz Somech; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 5.  Distinct Effects of Type I and III Interferons on Enteric Viruses.

Authors:  Harshad Ingle; Stefan T Peterson; Megan T Baldridge
Journal:  Viruses       Date:  2018-01-20       Impact factor: 5.048

6.  Oncolytic virus-derived type I interferon restricts CAR T cell therapy.

Authors:  Laura Evgin; Amanda L Huff; Phonphimon Wongthida; Jill Thompson; Tim Kottke; Jason Tonne; Matthew Schuelke; Katayoun Ayasoufi; Christopher B Driscoll; Kevin G Shim; Pierce Reynolds; Dileep D Monie; Aaron J Johnson; Matt Coffey; Sarah L Young; Gary Archer; John Sampson; Jose Pulido; Luis Sanchez Perez; Richard Vile
Journal:  Nat Commun       Date:  2020-06-24       Impact factor: 14.919

Review 7.  Porcine Interferon Complex and Co-Evolution with Increasing Viral Pressure after Domestication.

Authors:  Jordan Jennings; Yongming Sang
Journal:  Viruses       Date:  2019-06-15       Impact factor: 5.048

Review 8.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

9.  Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1.

Authors:  Chang-Long He; Ming Liu; Zhao-Xia Tan; Ya-Jun Hu; Qiao-Yue Zhang; Xue-Mei Kuang; Wei-Long Kong; Qing Mao
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

10.  Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Timokratis Karamitros; George Papatheodoridis; Dimitrios Paraskevis; Angelos Hatzakis; Jean L Mbisa; Urania Georgopoulou; Paul Klenerman; Gkikas Magiorkinis
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.